Brigham

Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts

Retrieved on: 
화요일, 8월 29, 2023
GE HealthCare, Therapy, Reder, Cone Health Women's Hospital, Cancer, Benveniste affair, Research, Harvard University, Harvard Medical School, Alpenglow, University Hospital Heidelberg, Patient, Cardiology, Diagnosis, Entrepreneurship, Hospital, Pharmacology, MPH, Summit, Laboratory, Medical imaging, Brigham, MD

CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.
  • The inaugural Summit stands to become the premier event focused on the emerging field of 3D Spatial Biology.
  • The event will encompass essential tools, data processing, and data analytics capabilities necessary for extracting meaningful biological insights to support scientific discovery and the advancement of life-saving therapeutics.
  • The 3D Spatial Summit features an impressive speaker list comprising key opinion leaders from academia and industry to offer varied perspectives on the burgeoning application of 3D spatial biology in answering pivotal disease-related questions.

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Retrieved on: 
금요일, 8월 25, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, MSD, Myocardial infarction, Amputation, Week, Cardiovascular disease, MRK, Lipid, Merck & Co., Harvard Medical School, Hypercholesterolemia, MD, Patient, Physician, Risk, LDL, PCSK9, Thrombolysis, Buerger's test, ASCVD, Moyamoya disease, Hospital, Death, NYSE, TIMI, Stroke, Pharmaceutical industry, Medicine, Brigham, Merck

This is the first Phase 3 clinical program for an oral PCSK9 inhibitor.

Key Points: 
  • This is the first Phase 3 clinical program for an oral PCSK9 inhibitor.
  • Merck also plans to initiate a Phase 3 cardiovascular outcomes study, CORALreef Outcomes by the end of 2023.
  • Merck is collaborating with the TIMI Study Group, a leading academic research organization for cardiovascular clinical trials, on the CORALreef Outcomes study.
  • Merck’s broad, global Phase 3 program for MK-0616 aims to enroll approximately 17,000 participants across the CORALreef Lipids, CORALreef HeFH and CORALreef Outcomes studies.

Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology

Retrieved on: 
수요일, 8월 23, 2023
Cone Health Women's Hospital, EA, ISNI, Coronavirus Scientific Advisory Board, PET, MS, Congress, MD, Patient, Mass, Mab, Mass General Brigham, DSM-IV codes, Hospital, AD, FDA, International Society, Pharmaceutical industry, Brigham

Dr. Weiner’s live presentation is scheduled for 11:42 a.m.

Key Points: 
  • Dr. Weiner’s live presentation is scheduled for 11:42 a.m.
  • "We are expanding our understanding of foralumab through rigorous research1 and clinical trials designed to study this potential treatment for neuroinflammatory diseases," said Howard L. Weiner, MD, Chairman of Tiziana's Scientific Advisory Board.
  • Dr. Weiner is also co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system.
  • Weiner’s presentation on foralumab, or nasal anti-CD3 mAb will also include updates on our Multiple Sclerosis Expanded Access (EA) program”, commented Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
화요일, 8월 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
화요일, 8월 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Histolix Appoints Jane Elizabeth Brock, MBBS, Ph.D. to Board of Directors

Retrieved on: 
화요일, 8월 22, 2023
Brock, Surgeon, Histology, University, MBBS, Cone Health Women's Hospital, Marie Cassidy, Pathology, UCD, Cancer, National Institutes of Health, Global health, Doctor of Philosophy, Harvard Medical School, National Cancer Institute, DP, Digital pathology, Knowledge, City, Hospital, Oncology, Health, FDA, NCI, Breast cancer, NIH, World Health Organization, Medical imaging, Brigham, MD

SACRAMENTO, Calif., Aug. 22, 2023 /PRNewswire-PRWeb/ -- Histolix, a leading developer of direct-to-digital read pathology solutions, today announced the appointment of Jane Elizabeth Brock, MBBS, Ph.D. to the company's board of directors. Brock brings more than 20 years of experience in pathology and is a specialist in diagnostic breast oncology. She is currently the chief of Breast Pathology Division, Brigham and Women's Hospital in Boston, and associate professor of Pathology at Harvard Medical School.

Key Points: 
  • SACRAMENTO, Calif., Aug. 22, 2023 /PRNewswire-PRWeb/ -- Histolix, a leading developer of direct-to-digital read pathology solutions, today announced the appointment of Jane Elizabeth Brock, MBBS, Ph.D. to the company's board of directors.
  • "Her vast background in pathology will help our ongoing endeavors to streamline histology procedures, helping shorten diagnostic pathology procedure outcomes from days to minutes.
  • She brings a wealth of knowledge to our highly esteemed clinical team currently working on this revolutionary digital pathology solution."
  • "The Histolix team is extremely well qualified to enable the next generation pathology solutions and ensure excellence in patient care."

Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease

Retrieved on: 
목요일, 8월 17, 2023
Interview, Phase II, Food and Drug Administration, Coronavirus Scientific Advisory Board, Inflammation, Foralumab, Investigational New Drug, Mass, DSM-IV codes, Hospital, FDA, IND, Neurology, Alzheimer's disease, Food, Neuroinflammation, Pharmaceutical industry, Brigham, Bloomberg

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.

Key Points: 
  • Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
  • Dr. Weiner is the Chairman of Tiziana's Scientific Advisory Board and his deep expertise and experience places him in a unique position to provide valuable insights into the potential impact of Tiziana's technology.
  • “Alzheimer's disease, a difficult-to-treat neurodegenerative disorder affecting millions worldwide, represents a significant unmet need and has long been a challenge in medical research,” stated Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
  • “Tiziana's commitment to innovation has driven us to explore novel solutions to this complex condition via intranasal foralumab, that, in previous studies, has been shown to modulate and dampen neuroinflammation.

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

Retrieved on: 
화요일, 8월 15, 2023
Flexner Report, Pathology, Brain, Harvard Medical School, Foralumab, Alzheimer's disease, Investigational New Drug, Patient, Mass, Neurology, DSM-IV codes, Hospital, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Disease, Pharmaceutical industry, Brigham

Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.

Key Points: 
  • Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, stated, "The IND clearance is a significant milestone for Tiziana that highlights the strength and the therapeutic potential of foralumab.
  • We are deeply committed to advancing the field of neurodegenerative diseases and bringing much-needed relief to patients suffering from Alzheimer's with a novel therapeutic approach.
  • Foralumab shows great promise in targeting the pathological hallmarks of the disease, and I am optimistic about its potential to offer a breakthrough treatment option for patients suffering from this devastating condition.

National Cancer Institute (NCI) Director, Monica M. Bertagnolli, M.D., Selected as Recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology

Retrieved on: 
수요일, 8월 16, 2023
Research, Women, Public Policy, Government, Philanthropy, White House, Federal Government, Consumer, Health, Foundation, Science, Oncology, National Foundation for Cancer Research, Survivor, Entrepreneurship, Drug development, University, Therapy, Women Leaders in Global Health Conference, Gastrointestinal cancer, AoC Beacon Awards, National Press Club (United States), Cancer, Quality of life, Biomedical Research, Press club, Woman, University of California, San Diego, Harvard Medical School, National Cancer Institute, Surgical oncology, Patient, Arizona State University, Bertagnolli, Diagnosis, NFCR, Director of the National Institutes of Health, Empathy, Complex adaptive system, NCI, NIH, Dana–Farber Cancer Institute, Pharmaceutical industry, Nursing, Management, Immunocore, Brigham

The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI) .

Key Points: 
  • The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of the 2023 AIM-HI Beacon Award for Women Leaders in Oncology as Monica M. Bertagnolli, M.D., Director of the National Cancer Institute (NCI) .
  • The Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund, a translational research and impact-investment affiliate of the National Foundation for Cancer Research (NFCR).
  • Dr. Bertagnolli will be honored as the 2023 AIM-HI Beacon Award recipient at a luncheon ceremony at the National Press Club in Washington, D.C., on October 21, 2023.
  • Tickets to attend the 2023 Global Summit and Award Ceremonies for Cancer Research and Entrepreneurship are now open for purchase.

Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT

Retrieved on: 
목요일, 7월 6, 2023
Antigen, Human, AMED, NEDO, Cone Health Women's Hospital, Teaching, New Energy and Industrial Technology Development Organization, Acute lymphoblastic leukemia, Cabinet Office, Massachusetts General Hospital, Research, Dopamine, Kyoto, Behavior, Lymphoma, MGB, Regenerative medicine, Harvard Medical School, Transplant, Department of Neurobiology, Harvard Medical School, Innovation Center station, Digital technology, Innovation system, Protein, Hospital, Parkinson's disease, MEXT, MD, Mass, FIRST, Immune system, Kyoto University, Cancer, Mass General Brigham, BWH, Ecosystem, Longevity, Rare, GCT, IPS, Gene, Medical research, United States Army Medical Research and Development Command, TSE, Disease, Pharmaceutical industry, Vaccine, Renewable energy, Science, Brigham

By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.

Key Points: 
  • By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.
  • Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT.
  • Mass General Brigham is a world-leading eco-system for GCT research and clinical trials, with over 400 researchers working on ground-breaking gene and cell therapy research and treatment in pursuit of potential cures.
  • From an early stage, Mass General Brigham has been actively engaged in GCT research, creating GCTI in December 2022.